Medifoxamine
An atypical antidepressant
| Medifoxamine | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | Hepatic |
| Elimination half-life | |
| Excretion | Renal |
| Legal status | Rx-only |
| CAS Number | 3239-44-9 |
| PubChem | 4053 |
| DrugBank | DB08998 |
| ChemSpider | 3913 |
| KEGG | D07355 |
Medifoxamine is an atypical antidepressant that was developed in the 1970s and used primarily in France and other European countries. It is known for its unique pharmacological profile, which distinguishes it from other antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).
Pharmacology[edit | edit source]
Medifoxamine acts as a serotonin and dopamine reuptake inhibitor, which contributes to its antidepressant effects. Unlike many other antidepressants, it does not significantly affect the reuptake of norepinephrine. This selective action is thought to reduce the incidence of certain side effects commonly associated with other antidepressant classes.
Additionally, medifoxamine has been shown to possess anxiolytic properties, making it potentially useful in the treatment of anxiety disorders. Its mechanism of action also includes modulation of GABAergic activity, which may contribute to its calming effects.
Clinical Use[edit | edit source]
Medifoxamine was primarily prescribed for the treatment of major depressive disorder and anxiety disorders. It was favored for its relatively mild side effect profile compared to other antidepressants available at the time. Patients reported fewer issues with sedation, weight gain, and sexual dysfunction, which are common side effects of many antidepressants.
Side Effects[edit | edit source]
While medifoxamine is generally well-tolerated, some patients may experience side effects such as nausea, dizziness, and headache. Rarely, it may cause allergic reactions or hepatic issues, necessitating regular monitoring of liver function during treatment.
Discontinuation[edit | edit source]
Medifoxamine was eventually withdrawn from the market due to concerns over hepatotoxicity, which is the potential for causing liver damage. Despite its efficacy and favorable side effect profile, the risk of liver damage led to its discontinuation in the late 1990s.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
